We believe that in the presence of oncogenic KRAS, the alt-EJ pathway is a key player in tumorigenesis, and loss of alt-EJ components may prevent or delay PanIN lesions development and, ultimately, pancreatic cancer progression. This evidence concerns the gene KRAS and pancreatic neoplasm.